- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real-world virologic outcomes of high BMI on CAB+RPV LA-I: A systematic review () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_1906;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Long-Acting Cabotegravir/Rilpivirine (CAB/RPV LA) in Older Adults with HIV: High Adherence and Low Complications in a Real-World Setting () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_1619;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real-World Efficacy and Tolerability of Long-Acting Cabotegravir/Rilpivirine in Woman with HIV and Polypharmacy plus Comorbidities () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_1378;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical outcomes at month 24 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND) () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_1245;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
High virologic suppression and few virologic failures with Long-Acting Cabotegravir + Rilpivirine in Treatment Experienced Virologically Suppressed Individuals from COMBINE-2 cohort in Europe () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_1122;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
The power of choice: strong preference for CAB+RPV LA following rapid suppression with DTG/3TC in newly diagnosed people living with HIV () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_1106;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Perspectives of healthcare providers on long-acting injectable cabotegravir and rilpivirine delivery in clinic and community settings in the UK: longitudinal survey findings from the ILANA study () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_1057;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
24-month outcomes of cabotegravir+rilpivirine long-acting every 2 months in a real?world setting: effectiveness, adherence to injections, and participant-reported outcomes from people with HIV-1 in the German CARLOS cohort () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_862;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Perspectives of people living with HIV (PWH) 24 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND) () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_669;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical outcomes among women in the OPERA Cohort initiating CAB+RPV LA with viral loads ? 50 copies/mL () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_649;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Rapid virologic suppression with DTG/3TC facilitates early switch to CAB+RPV LA for treatment-naive people living with HIV: Suppression Phase outcomes from the Phase 3b VOLITION study () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_567;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real-world effectiveness of CAB+RPV LA in individuals with HIV viremia at therapy initiation (Auditorium) - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_148;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Trial primary completion date: HOLA: Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine (clinicaltrials.gov) - May 9, 2025
P4, N=110, Active, not recruiting,
If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference. Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2025 --> Jun 2025
- |||||||||| Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical data, Journal, Real-world evidence: Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND). (Pubmed Central) - Apr 30, 2025
Proportions of participants reporting "always" or "often" experiencing challenges related to HIV-1 treatment (fear of disclosure, adherence anxiety, reminder of HIV-1 status, and feeling stigmatized) decreased from baseline to month 12. Month 12 results from the real-world BEYOND study support the effectiveness of CAB + RPV LA for maintenance of virologic suppression and as a preferred treatment option for people with HIV-1.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
PK/PD data, Journal: Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy. (Pubmed Central) - Apr 12, 2025
Model predictions suggest that monthly long-acting cabotegravir could maintain antiviral efficacy throughout pregnancy, but that bimonthly administration may require careful clinical evaluation. Both monthly and bimonthly long-acting rilpivirine may not adequately maintain antiviral efficacy in pregnancy.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Observational data, Journal, Real-world evidence: Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB?+?RPV Regimen: A Prospective Observational Study. (Pubmed Central) - Apr 10, 2025
In the subgroup, we found no significant changes in the HIV-DNA levels over time (p?=?0.332). Our results confirm the efficacy of CAB?+?RPV as a switch strategy in virologically suppressed PWH and even in more complex individuals, encouraging its use in PWH in need, coupled with HCA home administration support.
- |||||||||| Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Retrospective data, Journal, Real-world evidence: Real-world efficacy and tolerability of CAB+RPV LA in women: addressing the gender gap in HIV treatment research. (Pubmed Central) - Apr 2, 2025
CAB?+?RPV LA is effective and well-tolerated in women with complex ART histories, providing a viable long-acting alternative for populations traditionally underrepresented in clinical trials. These findings underscore the importance of including women in studies of novel ART regimens to ensure equitable access and outcomes.
- |||||||||| Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Transient Viremia Among People with HIV Receiving Injectable Cabotegravir Plus Rilpivirine. (Pubmed Central) - Apr 1, 2025
No other characteristics were significantly associated with time to VB, and no participants experienced virologic failure. Considerations for baseline CD4 may be important when initiating a patient on LAI CAB/RPV, and future studies will help evaluate the VB occurrence and associated factors among PWH.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir/Rilpivirine. (Pubmed Central) - Mar 17, 2025
Providers should consider LAI therapy among PWH with adherence difficulties. At-home administration of LA CAB/RPV by a healthcare provider was comparably safe, effective, and associated with high participant satisfaction relative to in-clinic administration.
- |||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical, Journal: Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic. (Pubmed Central) - Mar 12, 2025
In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi, Vemlidy (tenofovir alafenamide) / Gilead
Journal, Real-world evidence: The Real-World Impact of Long-Acting Injectable Cabotegravir-Rilpivirine on Weight and Renal Function. (Pubmed Central) - Mar 5, 2025
In this small set of patients, LAI CAB/RPV led to less weight gain compared to oral integrase inhibitor-based regimens. However, there was no significant change in the estimated glomerular filtration rate (eGFR) between patients who were started on LAI CAB/RPV and those who continued to receive oral regimens with or without tenofovir alafenamide (TAF).
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Characteristics of People With HIV Prescribed Long-Acting Cabotegravir/Rilpivirine in a US Cohort (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_1547;
Conclusions While each academic HIV clinic has been prescribing LA-CAB/RPV to underserved populations, including people with VNS and people who inject drugs, the rollout across clinics is uneven. Future scale-up efforts need to address access issues at the state/health system level to ensure that the diverse PWH populations that each clinic serves can benefit from LA-CAB/RPV.
- |||||||||| Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
A5359: Decreasing Oral Induction Duration in Support of LAI ART Use With Hardly Reached Populations (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_1288;
Of the 411 eligible for transition at the interim analysis, 61%, 77%, and 89% transitioned successfully to Step 2 with progressively shorter duration of viral suppression in Step 1(Table). Conclusions A5359 successfully enrolled a population not generally included in studies of investigational ART strategies and demonstrated that in-stream shortening of the required duration of virologic suppression significantly increased enrollment for the randomized strategy comparison.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Inter- and Intraindividual Variability of LA CAB/RPV Pharmacokinetics After 1 Year of Continuous Use (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_1281;
Conclusions After achieving proposed steady state concentrations, inter- and intraindividual variability persists for CAB and RPV. Despite this variability, there was no association between CAB/RPV concentrations and viremia.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Safety and Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Children 20 to 40 kg (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_1029;
Conclusions Administration of PO CAB+RPV followed by Q4W IM CAB-LA+RPV-LA in children 20-<40 kg achieved exposure concentrations comparable to adolescents and adults receiving this regimen. No new or unanticipated safety concerns were identified.
- |||||||||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Hepatitis B Reactivation in PWH With Isolated Anti-Core Pattern on Therapies Excluding Tenofovir (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_919;
Conclusions Our findings suggest that the risk of HBV reactivation in PLHIV with isolated anti-core patterns who are treated with TXF-free dual ART regimens is extremely low after more than 3 years of follow-up. This holds true even for regimens that do not have direct anti-HBV activity, such as DTG+RPV and CAB+RPV-LA.
- |||||||||| Edurant (rilpivirine) / J&J
Rilpivirine Drug-Resistant Mutations in Experienced Patients in Mexico: Impact on Long-Acting ART (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_912;
Conclusions This retrospective analysis indicates that rilpivirine DRMs are common in a setting wherein NNRTI-based treatment was widely implemented, and has implications for operational implementation of CAB/RPV LA. Screening for existing DRMs is logistically and technically challenging in Mexico and could be a barrier to use of CAB/RPV LA.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Distance to Care Measures Predict Injection Visit No-Shows Among Cabotegravir/Rilpivirine Recipients (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_896;
Conclusions Several DTC measures with CART-derived breakpoints were independently associated with IVNS among recipients of LAI CAB/RPV. Future studies should consider incorporating CART into the DTC measure used to predict injection visit adherence.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Implementation of LA-CAB/RPV in US Clinic Settings: A Survey of Front-Line Clinicians (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_895;
Conclusions While most clinicians surveyed have incorporated LA-CAB/RPV into their practices, key challenges remain, particularly among adolescents, cis-gender female patients, those with resolved Hepatitis B, and those with higher BMIs. Addressing barriers related to insurance and approval processes, along with continued education, is crucial to expanding access and optimizing the use of LA-CAB/RPV.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Outcomes in Those Who Discontinued Injectable Cabotegravir/Rilpivirine and Resumed Oral ART (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_894;
The percentage of those with HIV VL <50cpm and <200cpm up to 24 weeks was 91.4% and 94.8%, up to 48 weeks was 90.6% and 96.2%, and using the most recent documented VL was 91.9% and 95.9%, respectively. Conclusions In those who discontinued LAI CAB/RPV, returned to oral ART, and remained engaged in care, a high rate of ongoing viral suppression was observed.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Why Do People With HIV Stop Long-Acting Injectable Cabotegravir/Rilpivirine and What Happens? (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_892;
Conclusions Overall, discontinuation was low, and injection site pain was the most common reason. For PWH initiating LA-CAB/RPV with viremia, VF and missed/late injections accounted for over half of discontinuations, although most ultimately attained VS.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Outcomes of LAI ART for People With Detectable HIV Viremia in the NYC Public Healthcare System (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_891;
Background Long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) has changed the landscape of antiretroviral therapy (ART) by creating an alternative to daily oral ART...One limitation of our study is that the period of observation for follow up VLS varied for each patient, (e.g. our assessment included most recent viral load). Addressing barriers to LAI access, including expanding current FDA labeling to include certain patients with baseline viremia, is crucial to achieve VLS and improved health outcomes in this population.
- |||||||||| Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Low-Level Viremia and Risk Factors for Failure on Long-Acting Cabotegravir/Rilpivirine (LA CAB/RPV) (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_890;
This study is the first to report that low-level viremia was not associated with virologic failure in clinical practice. Further research is needed to identify those at risk of virologic failure and to develop optimal prevention strategies.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Impact of Oral Lead-In on PK and Virologic Outcomes in People With HIV Transitioning to CAB+RPV LA (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_889;
Secondary analyses of participants with baseline VL<20 cp/mL (N=147) showed similar trends. Conclusions In conclusion, the use of an oral lead-in did not result in significant differences in pharmacokinetics or virological outcomes for PWH transitioning to CAB+RPV LA over 9 months.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Long-Acting Cabotegravir/Rilpivirine in Real Life: Sex-Based Characteristics, PROs, and Effectiveness (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_887;
Conclusions In conclusion, the use of an oral lead-in did not result in significant differences in pharmacokinetics or virological outcomes for PWH transitioning to CAB+RPV LA over 9 months. Background This study aimed to focus on sex-based characteristics, patient reported outcomes (PROs) and effectiveness in people with HIV switching to long-acting cabotegravir-rilpivirine (LA-CAB/RPV) administered Q2M in Hospital Cl
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Long-Acting Cabotegravir and Rilpivirine in Older People With HIV in the GEPPO Cohort (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_886;
Background The association of intramuscularly administered Long-acting cabotegravir and rilpivirine (LA CAB+RPV) has been proven to be effective and safe in the maintenance treatment of people with HIV (PWH)...The pre-switch regimen was mainly based on a three-drug combination in 53.5% of study participants (mostly bictegravir or rilpivirine-based) or two-drug combinations by 45.1% (mostly dolutegravir/rilpivirine and dolutegravir/lamivudine)...Conclusions Our results suggest that the LA CAB+RPV combination is effective and safe in OPWH despite a long history of ART and a high prevalence of multimorbidity and polypharmacy. Older age should not be a barrier to the LA regimen: this study paves the way to evaluate the risk of an ageism attitude when clinicians consider ART choices in older PWH.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_885;
Conclusions A diverse population of women with HIV was able to receive CAB+RPV LA on-time and remain suppressed in this real-world study. Confirmed virologic failure was infrequent in these antiretroviral experienced women.
- |||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Long-Term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort (Poster Hall) - Mar 3, 2025 - Abstract #CROI2025CROI_883;
Suppressed PWH on CAB+RPV LA had favorable virologic outcomes as most maintained VLs <50 c/mL and CVF was infrequent. Further, virologic suppression was maintained regardless of BMI category at initiation.
|
